Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Daiichi Sankyo Company, Limited
  6. News
  7. Summary
    4568   JP3475350009

DAIICHI SANKYO COMPANY, LIMITED

(4568)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Daiichi Sankyo Company, Limited Announces New Data for valemetostat

06/11/2021 | 10:00am EDT

Daiichi Sankyo Company, Limited announced that new data for valemetostat, a potential first-in-class specific and potent dual inhibitor of EZH1 and EZH2, showed promising and durable tumor response in patients with relapsed/refractory peripheral T-cell lymphoma (PTCL) and adult T-cell leukemia/lymphoma (ATL).1,2 The data were reported on June 11, 2021 during an oral presentation (Abstract #S218) at the Annual Congress of the European Hematology Association. PTCL is a group of rare and heterogenous malignancies, including ATL, which represent about 10-15% of all non-Hodgkin lymphomas (NHL).3 The majority of patients with PTCL experience disease progression following initial treatment with a multi-drug chemotherapy-based regimen, and median overall survival following relapse is approximately 5.8 months.4 New innovative treatment strategies are needed to improve survival in these patients. In this first-in-human phase 1 study of valemetostat in B-cell and T-cell NHL, data were reported at EHA in the subset of patients with relapsed/refractory PTCL and ATL. The objective response rate (ORR), based on investigator’s assessment, was 54.5% (CI 95%: 38.8-69.6) in 44 patients with PTCL including 12 complete responses (CRs) and 12 partial responses (PRs). A median duration of response (DOR) of 56.00 weeks (CI 95%: 44.43-NE) and a median progression-free survival (PFS) of 52.00 weeks (CI 95%: 16.14-NE) were observed after a median follow-up of 19.93 weeks (range: 3.1-68.1). The ORR in 14 patients with ATL was 57.1% (CI 95%: 28.9-82.3), with four CRs and four PRs. Median DOR and PFS were not estimable for patients with ATL after a median follow-up of 23.07 weeks (range: 3.3-125.0). Twelve patients with PTCL and six patients with ATL remained on treatment with valemetostat at the time of data cutoff on November 2, 2020. The safety profile of valemetostat in patients with PTCL and ATL (n=58) was similar with that seen across all patients with NHL (n=77). Grade 3 or higher treatment emergent adverse events (TEAEs) occurred in 54 of 77 NHL patients (70.1%) and included neutrophil count decrease (23.4%), lymphocyte count decrease (22.1%), platelet count decrease (16.9%), white blood cell count decrease (15.6%), anemia (11.7%), diarrhea (1.3%) and alanine aminotransferase (ALT) increase (1.3%). Dose interruption or reductions due to TEAEs occurred in 41.6% (n=32) and 10.4% (n=8) of all patients with NHL, respectively. Patients with PTCL enrolled in the study had received a median of two prior treatments (range: 1-8), including prior hematopoietic stem cell transplantation (HSCT; 20.5%). Patients with ATL had received a median of two prior treatments (range: 1-8), including HSCT (14.3%).


ę S&P Capital IQ 2021
All news about DAIICHI SANKYO COMPANY, LIMITED
06:04aNikkei 225 Falls 2.2% on China Property Outlook
MT
09/20Japanese shares fall on Evergrande jitters; bargain-hunting limits losses
RE
09/20DAIICHI SANKYO : Enhertu reduced the risk of disease progression or death by 72% vs. trast..
AQ
09/20DAIICHI SANKYO : Enhertu demonstrated robust and durable tumour response of 54.9% in patie..
AQ
09/20ASTRAZENECA : Touts Positive Survival Data for Cancer Therapies Imfinzi, Enhertu
MT
09/20DAIICHI SANKYO : Enhertu demonstrated clinically meaningful and durable response in patien..
AQ
09/20ASTRAZENECA : Daiichi Sankyo's Enhertu Reduces Breast Cancer Death In Late-Stage Study
MT
09/20ASTRAZENECA : Daiichi Sankyo's Enhertu Shows 55% Tumor Response Rate in Lung Cancer Patien..
MT
09/20ASTRAZENECA : Daiichi Sankyo's Enhertu Prolongs Survival in Mid-Stage Gastric Cancer Study
MT
09/18DAIICHI SANKYO : ENHERTU« Reduced the Risk of Disease Progression or Death by 72% Versus T..
BU
More news
Analyst Recommendations on DAIICHI SANKYO COMPANY, LIMITED
More recommendations
Financials
Sales 2022 1 003 B 9 182 M 9 182 M
Net income 2022 58 841 M 539 M 539 M
Net cash 2022 630 B 5 771 M 5 771 M
P/E ratio 2022 99,1x
Yield 2022 0,88%
Capitalization 5 788 B 52 973 M 52 974 M
EV / Sales 2022 5,14x
EV / Sales 2023 4,84x
Nbr of Employees 16 033
Free-Float 97,6%
Chart DAIICHI SANKYO COMPANY, LIMITED
Duration : Period :
Daiichi Sankyo Company, Limited Technical Analysis Chart | 4568 | JP3475350009 | MarketScreener
Technical analysis trends DAIICHI SANKYO COMPANY, LIMITED
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 13
Last Close Price 3 020,00 JPY
Average target price 3 526,15 JPY
Spread / Average Target 16,8%
EPS Revisions
Managers and Directors
Sunao Manabe President, CEO & Representative Director
Hiroyuki Okuzawa CFO, Director, Executive Officer & Head-Management
Ken Takeshita Global Director-Research & Development
Noritaka Uji Independent Outside Director
Tsuguya Fukui Independent Outside Director
Sector and Competitors
1st jan.Capi. (M$)
DAIICHI SANKYO COMPANY, LIMITED-14.57%49 095
JOHNSON & JOHNSON4.09%431 227
ROCHE HOLDING AG10.52%321 941
PFIZER, INC.19.23%247 816
NOVO NORDISK A/S48.69%229 255
ELI LILLY AND COMPANY37.20%210 000